Bio-Rad Grants Beckman Coulter Exclusive Distribution for Two Infectious Disease Tests
By LabMedica International staff writers Posted on 27 Apr 2015 |
Bio-Rad Laboratories, Inc. (Hercules, CA, USA), a global provider of life science research and clinical diagnostic products, and clinical diagnostics leader Beckman Coulter Diagnostics (Brea, CA, USA), have announced that Bio-Rad is extending its agreement with Beckman Coulter and has named the company exclusive global distributor of Bio-Rad’s Access HIV combo assay and Access Hepatitis C virus (HCV) assay in select geographies. The products are currently not available in the US or Vietnam.
The 10-year exclusive distribution rights agreement is part of an extension of the manufacturing and supply agreement that began nearly 20 years ago for blood virus and infectious disease immunodiagnostic testing.
“This partnership with Bio-Rad enables Beckman Coulter Diagnostics to deliver on its commitment to customers by providing a broad immunoassay menu that allows them to optimize laboratory workflow,” said John Blackwood, senior vice president, Chemistry and Immunoassay Business Unit, Beckman Coulter Diagnostics, “With the new HIV combo assay and HCV assay running on the Beckman Coulter UniCel DxI and Access systems, we enable physicians to better diagnose and treat patients with blood viruses and infectious diseases.”
“We are pleased to extend our partnership with Beckman Coulter Diagnostics and believe the expertise of our respective organizations will add significant contributions to both HIV and hepatitis C testing laboratories and ultimately patient care,” said John Hertia, Bio-Rad executive vice president and Clinical Diagnostics Group president, “The strengthening of our partnership reflects each organization’s commitment in providing high-value testing for these diseases.”
Related Links:
Beckman Coulter Diagnostics
Bio-Rad Laboratories
The 10-year exclusive distribution rights agreement is part of an extension of the manufacturing and supply agreement that began nearly 20 years ago for blood virus and infectious disease immunodiagnostic testing.
“This partnership with Bio-Rad enables Beckman Coulter Diagnostics to deliver on its commitment to customers by providing a broad immunoassay menu that allows them to optimize laboratory workflow,” said John Blackwood, senior vice president, Chemistry and Immunoassay Business Unit, Beckman Coulter Diagnostics, “With the new HIV combo assay and HCV assay running on the Beckman Coulter UniCel DxI and Access systems, we enable physicians to better diagnose and treat patients with blood viruses and infectious diseases.”
“We are pleased to extend our partnership with Beckman Coulter Diagnostics and believe the expertise of our respective organizations will add significant contributions to both HIV and hepatitis C testing laboratories and ultimately patient care,” said John Hertia, Bio-Rad executive vice president and Clinical Diagnostics Group president, “The strengthening of our partnership reflects each organization’s commitment in providing high-value testing for these diseases.”
Related Links:
Beckman Coulter Diagnostics
Bio-Rad Laboratories
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance